Table 1 Baseline demographic and clinical characteristics (safety population)
Characteristic | Statistics | Placebo (n = 25) | TLC599 12 mg (n = 26) | TLC599 18 mg (n = 24) |
|---|---|---|---|---|
Age (years) | Mean (SD) | 64.8 (8.45) | 63.9 (9.07) | 62.9 (8.80) |
Gender | ||||
Male | n (%) | 7 (28.0) | 11 (42.3) | 7 (29.2) |
Female | n (%) | 18 (72.0) | 15 (57.7) | 17 (70.8) |
Race | ||||
Asian | n (%) | 12 (48.0) | 13 (50.0) | 12 (50.0) |
Australian aboriginal | n (%) | 0 | 0 | 1 (4.2) |
Caucasian | n (%) | 13 (52.0) | 13 (50.0) | 11 (45.8) |
Country | ||||
AU | n (%) | 13 (52.0) | 13 (50.0) | 12 (50.0) |
TW | n (%) | 12 (48.0) | 13 (50.0) | 12 (50.0) |
BMI (kg/m2) | Mean (SD) | 27.93 (4.655) | 27.65 (4.286) | 27.96 (5.114) |
Baseline VAS score (study knee) | Mean (SD) | 6.56 (1.049) | 6.45 (1.113) | 6.87 (1.215) |
Baseline WOMAC-Pain subscale score (0–4) | Mean (SD) | 1.62 (0.609) | 1.49 (0.558) | 1.74 (0.631) |
Baseline WOMAC-Function subscale score (0–4) | Mean (SD) | 1.48 (0.652) | 1.53 (0.531) | 1.82 (0.742) |
Knee pain | ||||
Bilateral | n (%) | 15 (60.0) | 16 (61.5) | 15 (62.5) |
Unilateral | n (%) | 10 (40.0) | 10 (38.5) | 9 (37.5) |
KL grade | ||||
2 | n (%) | 9 (36.0) | 13 (50.0) | 9 (37.5) |
3 | n (%) | 16 (64.0) | 13 (50.0) | 15 (62.5) |